These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 25733005)

  • 1. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
    Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
    Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
    Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
    Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
    Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM; Berger AJ; Burke K; Mulligan G; Dezube BJ; Harvey RD
    Clin Cancer Res; 2016 Feb; 22(4):847-57. PubMed ID: 26423795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
    Swords RT; Watts J; Erba HP; Altman JK; Maris M; Anwer F; Hua Z; Stein H; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC; DeAngelo DJ
    Blood Cancer J; 2017 Feb; 7(2):e520. PubMed ID: 28157218
    [No Abstract]   [Full Text] [Related]  

  • 5. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
    Swords RT; Coutre S; Maris MB; Zeidner JF; Foran JM; Cruz J; Erba HP; Berdeja JG; Tam W; Vardhanabhuti S; Pawlikowska-Dobler I; Faessel HM; Dash AB; Sedarati F; Dezube BJ; Faller DV; Savona MR
    Blood; 2018 Mar; 131(13):1415-1424. PubMed ID: 29348128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
    Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
    Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
    Zhou X; Friedlander S; Kupperman E; Sedarati F; Kuroda S; Hua Z; Yuan Y; Yamamoto Y; Faller DV; Haikawa K; Nakai K; Bowen S; Dai Y; Venkatakrishnan K
    Clin Transl Sci; 2021 May; 14(3):1069-1081. PubMed ID: 33503305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine.
    Handa H; Cheong JW; Onishi Y; Iida H; Kobayashi Y; Kim HJ; Chiou TJ; Izutsu K; Tsukurov O; Zhou X; Faessel H; Yuan Y; Sedarati F; Faller DV; Kimura A; Wu SJ
    J Hematol Oncol; 2022 May; 15(1):56. PubMed ID: 35545778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
    Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
    Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study assessing the mass balance, pharmacokinetics, and excretion of [
    Zhou X; Sedarati F; Faller DV; Zhao D; Faessel HM; Chowdhury S; Bolleddula J; Li Y; Venkatakrishnan K; Papai Z
    Invest New Drugs; 2021 Apr; 39(2):488-498. PubMed ID: 33089874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
    Faessel H; Nemunaitis J; Bauer TM; Lockhart AC; Faller DV; Sedarati F; Zhou X; Venkatakrishnan K; Harvey RD
    Br J Clin Pharmacol; 2019 Jul; 85(7):1464-1473. PubMed ID: 30845347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
    Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
    J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
    Foster JH; Reid JM; Minard C; Woodfield S; Denic KZ; Isikwei E; Voss SD; Nelson M; Liu X; Berg SL; Fox E; Weigel BJ
    Eur J Cancer; 2024 Sep; 209():114241. PubMed ID: 39096851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors.
    Yamamoto N; Shimizu T; Yonemori K; Kitano S; Kondo S; Iwasa S; Koyama T; Sudo K; Sato J; Tamura K; Tomomatsu J; Ono M; Fukuda N; Takahashi S
    Invest New Drugs; 2021 Aug; 39(4):1036-1046. PubMed ID: 33560503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.
    Wei LY; Wu ZX; Yang Y; Zhao M; Ma XY; Li JS; Yang DH; Chen ZS; Fan YF
    Exp Cell Res; 2020 Mar; 388(2):111858. PubMed ID: 31972220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
    Snow A; Zeidner JF
    Ther Adv Hematol; 2022; 13():20406207221112899. PubMed ID: 35898435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and Disposition of [
    Bolleddula J; Chen H; Cohen L; Zhou X; Pusalkar S; Berger A; Sedarati F; Venkatakrishnan K; Chowdhury SK
    Drug Metab Dispos; 2022 Jul; 50(7):989-997. PubMed ID: 35504658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
    Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
    Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.